Ítem
Acceso Abierto

Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease

Mostrar el registro sencillo de la publicación
dc.creatorRodríguez Velandia, Yhojan Alexisspa
dc.creatorVatti N.spa
dc.creatorRamírez Santana, Heily Carolinaspa
dc.creatorChang C.spa
dc.creatorMancera-Páez O.spa
dc.creatorGershwin M.E.spa
dc.creatorAnaya, Juan-Manuelspa
dc.date.accessioned2020-05-25T23:55:51Z
dc.date.available2020-05-25T23:55:51Z
dc.date.created2019spa
dc.description.abstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease characterized by neurological symptoms and signs of progressive weakness, paresthesias, and sensory dysfunction. Other symptoms include reduced or absent tendon reflexes, cranial nerve involvement, autonomic symptoms, ataxia, and neuropathic pain. Unlike other autoimmune diseases, CIDP generally affects older individuals and has a male predominance. The onset is generally insidious and can take up to 8 weeks with a relapsing-recovery pattern. Like all autoimmune diseases, the etiology is multifactorial, with both genetic and environmental factors contributing to it. Case reports of CIDP have found associations with multiple pathogenic organisms including Hepatitis B and C viruses, Bartonella henselae, Mycoplasma pneumoniae, Human immunodeficiency virus, Cytomegalovirus and Epstein-Barr virus. Possible antigenic self-targets include myelin protein 0, myelin protein 2, peripheral myelin protein 22, Connexin 32, and myelin basic protein. Antibodies targeting the Ranvier node proteins such as contactin-1, contactin-associated protein 1, and neurofascin 155 have been described. CIDP is treated with rehabilitation and pharmacological modalities. Pharmacological treatments target autoimmune dysfunction and include corticosteroids, intravenous immunoglobulin, subcutaneous immunoglobulin, plasma exchange, immunosuppressive and immunomodulatory agents such as methotrexate, cyclophosphamide, rituximab, and mycophenolate mofetil. Although there are few observational studies and randomized clinical trials with limited evidence supporting the use of immunosuppressive drugs, they are widely used in clinical practice. A comprehensive review of CIDP is presented herein in light of the autoimmune tautology. © 2019 Elsevier Ltdeng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.jaut.2019.04.021
dc.identifier.issn10959157
dc.identifier.issn08968411
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22243
dc.language.isoengspa
dc.publisherAcademic Pressspa
dc.relation.citationEndPage37
dc.relation.citationStartPage8
dc.relation.citationTitleJournal of Autoimmunity
dc.relation.citationVolumeVol. 102
dc.relation.ispartofJournal of Autoimmunity, ISSN:10959157, 08968411, Vol.102,(2019); pp. 8-37spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065064435&doi=10.1016%2fj.jaut.2019.04.021&partnerID=40&md5=e5e2fbdac2a158ae69073f06b26754baspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordConnexin 32spa
dc.subject.keywordContactin 1spa
dc.subject.keywordContactin associated protein 1spa
dc.subject.keywordCorticosteroid derivativespa
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordImmunoglobulinspa
dc.subject.keywordMethotrexatespa
dc.subject.keywordMycophenolate mofetilspa
dc.subject.keywordMyelin basic proteinspa
dc.subject.keywordMyelin proteinspa
dc.subject.keywordNeurofascin 155spa
dc.subject.keywordPeripheral myelin protein 22spa
dc.subject.keywordRituximabspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordAdaptive immunityspa
dc.subject.keywordAtaxiaspa
dc.subject.keywordBartonella henselaespa
dc.subject.keywordChronic inflammatory demyelinating polyneuropathyspa
dc.subject.keywordClinical featurespa
dc.subject.keywordClinical practicespa
dc.subject.keywordCytomegalovirusspa
dc.subject.keywordEnvironmental factorspa
dc.subject.keywordEpstein barr virusspa
dc.subject.keywordHepatitis b virusspa
dc.subject.keywordHepatitis c virusspa
dc.subject.keywordHeredityspa
dc.subject.keywordHumanspa
dc.subject.keywordHuman immunodeficiency virusspa
dc.subject.keywordHumoral immunityspa
dc.subject.keywordImmunosuppressive treatmentspa
dc.subject.keywordMycoplasma pneumoniaespa
dc.subject.keywordNerve conductionspa
dc.subject.keywordNeuropathic painspa
dc.subject.keywordParesthesiaspa
dc.subject.keywordPathogenesisspa
dc.subject.keywordPlasma exchangespa
dc.subject.keywordPriority journalspa
dc.subject.keywordRanvier nodespa
dc.subject.keywordReflex disorderspa
dc.subject.keywordReviewspa
dc.subject.keywordSensory dysfunctionspa
dc.subject.keywordTendon reflexspa
dc.subject.keywordWeaknessspa
dc.subject.keywordAutoimmune diseasespa
dc.subject.keywordAutoimmune ecologyspa
dc.subject.keywordAutoimmune tautologyspa
dc.subject.keywordChronic inflammatory demyelinating polyradiculoneuropathyspa
dc.subject.keywordGuillain-barré syndromespa
dc.subject.keywordMolecular mimicryspa
dc.subject.keywordPolyautoimmunityspa
dc.titleChronic inflammatory demyelinating polyneuropathy as an autoimmune diseasespa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1-s2-0-S0896841119300435-main.pdf
Tamaño:
1.35 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos